Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Abiomed Inc Stock Research

ABMD

Market Closed
Watchlist

ABMD Stock Price

ABMD RSI Chart

ABMD Valuation

Market Cap

17.2B

Price/Earnings (Trailing)

64.52

Price/Sales (Trailing)

16.02

EV/EBITDA

46.18

Price/Free Cashflow

79.23

ABMD Price/Sales (Trailing)

ABMD Profitability

Free Cashflow Yield

1.26%

ABMD Fundamentals

ABMD Revenue

ABMD Earnings

Price Action

Last 7 days

0.2%

Last 30 days

1.2%

Last 90 days

54.1%

Trailing 12 Months

14.7%

ABMD Financial Health

ABMD Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ABMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-02-17
Rolle Myron L
sold (taxes)
-36,447
325
-112
-
2022-02-17
SUTTER MARTIN P
sold
-1,258,850
314
-4,000
-
2022-02-16
SUTTER MARTIN P
sold
-617,322
308
-2,000
-
2022-02-16
Weber David M
sold
-2,437,500
325
-7,500
chief operating officer
2022-02-15
SUTTER MARTIN P
sold
-607,301
303
-2,000
-
2022-02-09
Weber David M
acquired
67,063
21.55
3,112
chief operating officer
2022-02-09
Weber David M
sold
-965,311
310
-3,112
chief operating officer
2022-02-08
Weber David M
acquired
159,750
21.55
7,413
chief operating officer
2022-02-08
Weber David M
sold
-2,245,420
302
-7,413
chief operating officer
2022-02-07
Weber David M
acquired
6,465
21.55
300
chief operating officer

1–10 of 50

Which funds bought or sold ABMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
sold off
-100
-1,501,000
-
-%
2023-08-11
HUNTINGTON NATIONAL BANK
unchanged
-
-
381
-%
2023-03-17
American Portfolios Advisors
reduced
-10.72
-21,822
169,751
0.01%
2023-02-13
SEEYOND
sold off
-100
-954,000
-
-%
2023-02-13
HERITAGE WEALTH MANAGEMENT, LLC
sold off
-100
-10,000
-
-%
2023-02-06
Brinker Capital Investments, LLC
sold off
-100
-2,066,000
-
-%
2023-01-24
Autus Asset Management, LLC
sold off
-100
-3,702,000
-
-%
2022-11-21
17 CAPITAL PARTNERS, LLC
unchanged
-
-2,000
281,000
0.38%
2022-11-21
FourThought Financial, LLC
reduced
-6.88
-6,000
73,000
0.01%
2022-11-15
Covington Capital Management
new
-
1,000
1,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying ABMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABMD
No. of Funds

Schedule 13G FIlings of Abiomed

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 06, 2023
baillie gifford & co
0.01%
2,991
SC 13G/A
Dec 29, 2022
millennium management llc
0.0%
0
SC 13G
Feb 09, 2022
vanguard group inc
10.64%
4,842,984
SC 13G/A
Feb 04, 2022
wellington management group llp
5.41%
2,461,221
SC 13G
Jan 18, 2022
baillie gifford & co
8.44%
3,839,980
SC 13G/A
Jan 10, 2022
blackrock inc.
10.1%
4,592,566
SC 13G/A
Feb 16, 2021
sands capital management, llc
3.27%
1,479,909
SC 13G
Feb 10, 2021
renaissance technologies llc
4.41%
1,993,800
SC 13G/A
Feb 10, 2021
vanguard group inc
10.63%
4,801,759
SC 13G/A
Jan 29, 2021
blackrock inc.
9.1%
4,127,359
SC 13G/A

Peers (Alternatives to Abiomed)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
109.7B
19.5B
4.61% 32.58%
40.5
5.64
10.36% 30.30%
102.6B
6.7B
1.85% 46.31%
71.98
15.39
11.75% -0.66%
78.2B
13.4B
7.30% 33.81%
85.79
5.84
8.69% 3.17%
71.3B
19.0B
-3.08% 10.26%
44.09
3.79
0.46% -5.24%
43.7B
5.7B
-5.74% -17.48%
31.48
7.73
5.64% -4.53%
MID-CAP
10.1B
937.8M
5.52% 36.72%
345.25
10.72
16.30% 250.21%
7.5B
616.6M
-7.14% -29.65%
30.68
12.13
69.52% 343.68%
5.3B
1.1B
-4.57% -12.56%
25.23
4.84
12.63% 50.85%
2.7B
452.1M
-16.85% -42.51%
-27.51
6.04
24.99% 24.09%
1.5B
790.3M
-18.06% -57.30%
-6.6
1.87
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-8.54% 49.60%
-9.62
3.81
44.49% -2.43%
952.1M
780.7M
-7.00% -11.88%
-26.45
1.22
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
620.2M
162.9M
-26.12% -63.06%
-11.73
3.81
42.67% 12.82%

Abiomed News

Investor's Business Daily
More Than A Third Of S&P 500 Stocks Get Kicked Out In Nine Years.
Investor's Business Daily,
14 days ago
Diagnostic and Interventional Cardiology
Lankenau Medical Center Performs First Minimally Invasive ....
Diagnostic and Interventional Cardiology,
3 months ago
Diagnostic and Interventional Cardiology
Excellent 12-Month Results from SELUTION SFA Trial Presented at ....
Diagnostic and Interventional Cardiology,
3 months ago
Diagnostic and Interventional Cardiology
MedAlliance Enrolls First US Patient into its Third FDA IDE Study ....
Diagnostic and Interventional Cardiology,
4 months ago
Diagnostic and Interventional Cardiology
Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI ....
Diagnostic and Interventional Cardiology,
6 months ago
Diagnostic and Interventional Cardiology
Datascope/Getinge Recalls Cardiosave Hybrid and Rescue Intra ....
Diagnostic and Interventional Cardiology,
7 months ago
Mass Device
Johnson & Johnson

Returns for ABMD

Cumulative Returns on ABMD

39.5%


10-Year Cumulative Returns

23.2%


7-Year Cumulative Returns

14.7%


5-Year Cumulative Returns

32.7%


3-Year Cumulative Returns

Risks for ABMD

What is the probability of a big loss on ABMD?

80%


Probability that Abiomed stock will be more than 20% underwater in next one year

58.1%


Probability that Abiomed stock will be more than 30% underwater in next one year.

31.5%


Probability that Abiomed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abiomed was unfortunately bought at previous high price.

Drawdowns

Financials for Abiomed

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Revenue1.7%1,0741,0561,0321,003974935848813803798841841820797769737690641594544505
Cost Of Revenue-------------------99.0088.0082.00
Costs and Expenses2.5%820800891865828789618588579576592585572558545530501470437405385
  S&GA Expenses3.2%452438423414393369334318317324342339334326322316302283263247235
  R&D Expenses0.6%16716616315214413312211510810199.0099.0097.0096.0094.0089.0083.0080.0075.0070.0069.00
EBITDA23.9%369298219217239243313278293237278335301--------
EBITDA Margin21.9%0.34*0.28*0.21*0.22*0.25*0.26*0.37*0.34*0.37*0.30*0.33*0.40*0.37*--------
Interest Expenses-------------------0.000.001.00
Earnings Before Taxes26.5%341270191189212218288254270215257316284318263213194175160141121
EBT Margin24.4%0.32*0.26*0.18*0.19*0.22*0.23*0.34*0.31*0.34*0.27*0.31*0.38*0.35*--------
Net Income22.6%26721813713314915422620020815920324522125825922219016511290.0092.00
Net Income Margin20.6%0.25*0.21*0.13*0.13*0.15*0.17*0.27*0.25*0.26*0.20*0.24*0.29*0.27*--------
Free Cashflow-17.3%217263250246233248221237246240271257243--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Assets-0.4%1,6971,7041,6731,5931,5301,4581,4941,4281,3281,2501,2161,1971,1241,1251,054957887812786720695
  Current Assets0.2%1,0631,060976885871730788694717620636637647677677629562497494422370
    Cash Equivalents1.0%18218013314424217523318120221519211815010112184.0076.0061.0043.0051.0045.00
  Inventory7.2%10295.0094.0090.0086.0084.0081.0082.0083.0089.0090.0091.0090.0088.0081.0072.0064.0056.0050.0047.0041.00
  Net PPE-1.7%19519820219719719819717917617016516215815214513813412711710898.00
  Goodwill-2.5%73.0075.0077.0077.0078.0079.0079.0080.0078.0077.0032.0033.0032.0033.0033.0033.0034.0034.0036.0035.0034.00
Liabilities-6.4%15716717016014515116516714614815115013312211710694.0089.0097.0087.0090.00
  Current Liabilities-4.8%13414113812711411312912010511013212611210010693.0082.0077.0085.0075.0063.00
Shareholder's Equity0.2%1,5401,5361,5031,4331,3851,3081,3301,2611,1821,1021,0651,0479911,003937852793723690632605
  Retained Earnings10.4%1,1251,01996590485880182877170964760257150148839932628123114010490.00
  Additional Paid-In Capital2.2%905885870853840815801782768749739733722705691676660638620606592
Shares Outstanding-0.9%45.0046.0046.0046.0045.0045.0045.0045.0045.0045.0045.0045.0045.0045.0045.0045.0045.0045.0044.0044.0044.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Cashflow From Operations-15.8%251298285293282298275275285282315299284270252238220203193173151
  Share Based Compensation0.5%54.0053.0053.0054.0055.0050.0047.0036.0034.0036.0040.0048.0053.0055.0054.0055.0051.0044.0040.0038.0033.00
Cashflow From Investing38.2%-162-263-380-324-250-346-223-177-168-65.76-125-171-139-197-116-149-135-128-180-181-158
Cashflow From Financing-626.0%-135-18.67-2.20-1.586.005.00-8.07-35.20-61.42-98.60-117-92.93-69.10-33.25-55.77-56.24-53.52-56.50-9.14-1.290.00
  Buy Backs772.2%25329.00----11.0036.0061.0096.0085.00120139--------

ABMD Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 265,921$ 248,142$ 543,070$ 500,727
Costs and expenses:    
Cost of revenue48,88043,886101,50689,074
Research and development42,08941,04182,56678,749
Selling, general and administrative116,958102,779234,954206,263
Acquired in-process research and development000115,490
Costs and Expenses, Total207,927187,706419,026489,576
Other (loss) income:    
Income from operations57,99460,436124,04411,151
Interest and other income, net80,7096,83584,48146,770
Income before income taxes138,70367,271208,52557,921
Income tax provision32,57010,31847,83827,493
Net income$ 106,133$ 56,953$ 160,687$ 30,428
Net income per share - basic$ 2.34$ 1.25$ 3.53$ 0.67
Weighted average shares outstanding - basic45,37245,43745,47545,374
Net income per share - diluted$ 2.32$ 1.24$ 3.51$ 0.66
Weighted average shares outstanding - diluted45,71145,89345,81245,857

ABMD Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current assets:  
Cash and cash equivalents$ 182,335$ 132,818
Short-term marketable securities638,037625,789
Accounts receivable, net94,47590,608
Inventories, net102,23793,981
Prepaid expenses and other current assets45,71433,277
Total current assets1,062,798976,473
Long-term marketable securities116,871220,089
Property and equipment, net195,157202,490
Goodwill72,96076,786
Other intangibles, net36,83339,518
Deferred tax assets18,88110,552
Other assets193,044147,485
Total assets1,696,5441,673,393
Current liabilities:  
Accounts payable35,07035,346
Accrued expenses69,43472,629
Deferred revenue25,96226,362
Other current liabilities3,5944,120
Total current liabilities134,060138,457
Other long-term liabilities7,0139,319
Contingent consideration14,99521,510
Deferred tax liabilities689781
Total liabilities156,757170,067
Commitments and contingencies (Note 16)
Stockholders' equity:  
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively452455
Additional paid in capital904,755870,074
Retained earnings1,125,199964,512
Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively(443,974)(304,555)
Accumulated other comprehensive loss(46,645)(27,160)
Total stockholders' equity1,539,7871,503,326
Total liabilities and stockholders' equity$ 1,696,544$ 1,673,393
Michael R. Minogue
2000
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.